

NEUROLOGIX INC/DE  
Form NT 10-K  
March 29, 2004

---

**U.S. SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 12b-25**

**Commission File Number: 0-13347**

---

**NOTIFICATION OF LATE FILING**

(Check One):     Form 10-K and Form 10-KSB                       Form 20-F     Form 11-K  
                          Form 10-Q and Form 10-QSB                       Form N-SAR

For Period Ended: December 31, 2003

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I**

**REGISTRANT INFORMATION**

**Neurologix, Inc.**

**Full Name of Registrant**

---

**Former name if applicable**

**One Bridge Plaza**

**Address of principal executive office (Street and number)**

**Fort Lee, New Jersey, 07024**

**City, State and Zip Code**

---

**PART II**

**RULE 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- [X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- [X] (b) The subject annual report, semi-annual report, transition report on Form 10-K or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III**

**NARRATIVE**

State below in reasonable detail the reasons why Form 10-K, 11K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed period. (Attach extra sheets if needed.)

On February 9, 2004, the Registrant's stockholders adopted and approved a merger agreement (the Merger Agreement) by and among Neurologix, Inc. (formerly known as Change Technology Partners, Inc. and hereinafter to as the Registrant), CTP/N Merger Corp., a wholly-owned subsidiary of the Registrant and Neurologix Research, Inc. (formerly known as Neurologix, Inc. and hereinafter referred to as NRI), a privately held company. On February 10, 2004, the merger was completed and CTP/N Merger Corp. merged with and into NRI, with NRI as the surviving corporation. This transaction is being accounted for as a reverse merger. The Registrant is unable to complete the required financial statements for this period in a timely manner without unreasonable effort and expense, but expects to file the required report within the allocated extension.

**PART IV**

**OTHER INFORMATION**

- (1) Name and telephone number of person to contact in regard to this notification

Edgar Filing: NEUROLOGIX INC/DE - Form NT 10-K

Mark S. Hoffman

201

592-6451

---

Secretary and Treasurer  
(Name)

(Area Code) (Telephone Number)

- (2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the receding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).       Yes       No
- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?       Yes       No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**Neurologix, Inc.**

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date March 29, 2004

By /s/ MARK S. HOFFMAN

---

Secretary and Treasurer